Nutra Pharma Corp (NPHC)

[gempicker]

Gremlins exist in every OTC closet and every OTC investor needs to keep those in mind...

However... orphan drug status for pediatric MS is not a gremlin, neither is the potential treatment indications for other diseases... on top of that, the opioid awareness is growing and the Nyloxin product might just be the right place at the right time.

The savvy and the astute both understand past failures do not necessarily lead to future failures as many failed companies do breakthrough...

This stock is beginning to trade with a growing anticipation that a breakthrough is imminent that will give their non addictive pain therapies an even chance to assist those most in need while flourishing the company and investors into bigger and better... partnerships are hinted at... the horizon is looking a little bit brighter this month and into 2018...